Medicine Press release



Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 21, 2024 14:26 JST
Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.
More info..


Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2024 08:35 JST
Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
More info..


Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 16, 2024 08:31 JST
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
More info..


Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems
Feb 08, 2024 14:04 JST
Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers).
More info..


Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Feb 01, 2024 17:04 JST
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
More info..


BioAdaptives' Subsidiary, Livestock Impact, Inc. Celebrates Banner 2023 Equine Championship Titles Attributed to Its Advanced Proprietary Supplement Products
Feb 01, 2024 04:00 JST
Docs Dual Quixote, who secured the 35,000 Non Pro National Championship Title at the 2023 United States Cutting Horse Association (USCHA) National Championship annual competition in November.
More info..


Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Jan 26, 2024 15:26 JST
Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
More info..


Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
Jan 24, 2024 14:00 JST


Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
Jan 24, 2024 14:00 JST


Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
Jan 24, 2024 14:00 JST